(19)
(11) EP 3 388 529 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
26.12.2018 Bulletin 2018/52

(43) Date of publication:
17.10.2018 Bulletin 2018/42

(21) Application number: 18173838.6

(22) Date of filing: 03.12.2009
(51) International Patent Classification (IPC): 
C12Q 1/37(2006.01)
 C12Q 1/56(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 05.12.2008 US 120202 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09764426.4 / 2358895

(71) Applicants:
  • Baxalta GmbH
    6300 Zug (CH)
  • Baxalta Incorporated
    Bannockburn, IL 60015 (US)

(72) Inventors:
  • VARADI, Katalin
    1230 Vienna (AT)
  • ROTTENSTEINER, Hanspeter
    1020 Vienna (AT)
  • TURECEK, Peter
    3400 Klosterneuburg (AT)
  • SCHWARZ, Hans-Peter
    1180 Vienna (AT)
  • SCHREINER, Jutta
    1170 Vienna (AT)

(74) Representative: Bird & Bird LLP 
Maximiliansplatz 22
80333 München
80333 München (DE)

 
Remarks:
This application was filed on 23-05-2018 as a divisional application to the application mentioned under INID code 62.
 


(54) METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF


(57) The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.